- Report
- April 2026
- 140 Pages
Global
From €2690EUR$2,999USD£2,300GBP
€3587EUR$3,999USD£3,067GBP
- Report
- August 2026
- 189 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- November 2025
- 185 Pages
Global
From €4037EUR$4,500USD£3,451GBP
- Report
- February 2026
- 250 Pages
Global
From €4028EUR$4,490USD£3,443GBP
- Report
- August 2026
- 383 Pages
Global
From €5248EUR$5,850USD£4,486GBP
- Report
- May 2026
- 148 Pages
Global
From €3543EUR$3,950USD£3,029GBP
- Report
- August 2026
- 460 Pages
Global
From €4032EUR$4,495USD£3,447GBP
- Report
- August 2026
- 182 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- February 2026
- 250 Pages
Global
From €4028EUR$4,490USD£3,443GBP
- Report
- February 2026
- 250 Pages
Global
From €4028EUR$4,490USD£3,443GBP
- Report
- February 2026
- 250 Pages
Global
From €4028EUR$4,490USD£3,443GBP
- Report
- February 2026
- 250 Pages
Global
From €4028EUR$4,490USD£3,443GBP
- Report
- August 2026
- 206 Pages
Global
From €5248EUR$5,850USD£4,486GBP
- Report
- July 2026
- 135 Pages
Global
From €4261EUR$4,750USD£3,643GBP
- Report
- October 2025
- 90 Pages
Global
From €4037EUR$4,500USD£3,451GBP
- Report
- November 2024
- 265 Pages
Global
From €3745EUR$4,175USD£3,202GBP
- Report
- July 2023
- 152 Pages
Global
From €4171EUR$4,650USD£3,566GBP
- Report
- October 2025
- 133 Pages
Canada
From €4396EUR$4,900USD£3,758GBP
- Report
- April 2025
- 171 Pages
Global
From €4396EUR$4,900USD£3,758GBP
- Report
- March 2024
- 202 Pages
Global
From €4440EUR$4,950USD£3,796GBP

Minimal Residual Disease (MRD) Testing is a type of In Vitro Diagnostics (IVD) used to detect the presence of cancer cells in a patient's body. It is used to monitor the effectiveness of cancer treatments and to detect the recurrence of cancer. MRD testing is typically performed on a sample of bone marrow or peripheral blood, and can detect cancer cells at levels as low as one in a million. It is used to detect the presence of cancer cells in patients with leukemia, lymphoma, and multiple myeloma.
MRD testing is a rapidly growing market, driven by the increasing prevalence of cancer and the need for more accurate and sensitive diagnostic tests. The development of new technologies, such as next-generation sequencing and flow cytometry, has enabled more accurate and sensitive MRD testing.
Companies in the MRD testing market include Abbott, Agilent Technologies, Bio-Rad Laboratories, Becton Dickinson, and Roche Diagnostics. Show Less Read more